ArticleScientific reports2025
The role of biogenic aluminium oxide nanoparticles (Al
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial vaginosis results from an elevation in biofilm-forming vaginal bacteria. They provide a considerable clinical concern due to the rising global antibiotic resistance. This work investigated the antibacterial and anti-biofilm characteristics of Al₂O₃ NPs synthesised from Solanum virginianum L. Fourier. The characterisation techniques Fourier Transform Infrared Spectroscopy (FTIR), X-ray diffraction (XRD), Scanning Electron Microscopy (SEM), Ultraviolet-visible spectroscopy (UV-Vis), and Energy-dispersive X-ray spectroscopy (EDX) validated the synthesis and structural integrity of the nanoparticles. Marked antibacterial and antifungal efficacy was noted against 108 isolates of various microorganisms (G. vaginalis, S. aureus, E. coli, P. aeruginosa, and C. albicans). Al₂O₃ displayed minimum inhibitory concentrations (MICs) ranging from 1000 to 3000 µg/mL and MBC at 2000-5000 mg/mL against study strains. Al₂O₃ signicantly inhibited biofilm formation by 50%-75%, cell surface hydrophobicity by 50-60%, outer membrane disruption by 60%-70% and preform biofilm disruption by 50%-80% in the test strains at respective 0.5xMIC. Elevated levels of reactive oxygen species (ROS) generation in the Al₂O₃ -treated G. vaginalis, S. aureus, E. coli, P. aeruginosa, and C. albicans could be the possible cause of cell death leading to biofilm inhibition. The research identified a significant correlation between biofilm positive and age, exhibiting an odds ratio of 6.33 and a risk ratio of 2.28. Vulvar pruritus and oedema were correlated with biofilm positive, although secretion colour exhibited no significant relationships. These results may inform clinical care and therapeutic approaches. The findings indicate that biogenic Al₂O₃ NPsderived from S. virginianum offer an environmentally sustainable alternative to traditional antimicrobials for vaginal washing in the treatment of biofilm-mediated vaginal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.